RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC - Wikidata - awgldk - TriplyDB

RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC

RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC

http://www.wikidata.org/entity/Q34446751

about

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer Silencing of advanced glycosylation and glycosylation and product-specific receptor (RAGE) inhibits the metastasis and growth of non-small cell lung cancer A meta-analysis of the relationship between glutathione S-transferase T1 null/presence gene polymorphism and the risk of lung cancer including 31802 subjects.Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) is associated with poor prognosis in gastric cancer.Association of RAGE polymorphisms and cancer risk: a meta-analysis of 27 studies.Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer.Lung adenocarcinoma expressing receptor for advanced glycation end-products with primary systemic AL amyloidosis: a case report and literature review.Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case-control study.BMP-4 genetic variants and protein expression are associated with platinum-based chemotherapy response and prognosis in NSCLC.Critical role of RAGE in lung physiology and tumorigenesis: a potential target of therapeutic intervention?Association of epidermal growth factor receptor (EGFR) gene polymorphism with lung cancer risk: a systematic review.Knockdown of RAGE inhibits growth and invasion of gastric cancer cells.Genetically lowered concentrations of circulating sRAGE might cause an increased risk of cancer: Meta-analysis using Mendelian randomization.A multicenter matched case-control analysis on seven polymorphisms from HMGB1 and RAGE genes in predicting hepatocellular carcinoma risk.AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma.Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer.Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.Polymorphisms of the receptor for advanced glycation end-products and glyoxalase I in patients with renal cancer

P2860

Q26795466-50630A5E-3DDA-48CB-AA74-0C834E2EA0E2 Q33850230-DBB25A93-0CCB-48AF-8A29-E930472F4A73 Q35000534-0D67E69B-1C18-4E31-946B-D0FD0F6EEF22 Q35140467-707A7FD4-2C0A-413A-A1AB-EBFFF966EBAF Q35364536-21061CAE-73DA-4603-A9BE-C12709C8A818 Q35545467-F23F1AAF-6D8B-4AE8-8E30-AD93C07F5BD8 Q35803624-A0878FE5-4049-4E05-B041-B0574AD8F25B Q36240992-FB0324CA-4828-4F5A-992D-9D6872292F53 Q37627994-636865DF-ADD0-4F86-AFE6-2EBCEFDF1E1E Q37688183-EE801762-96EA-4A19-B1D1-A5A78B792605 Q38150990-03BCA5B0-139F-44E2-99F7-2EFF1C970290 Q38185151-7E8E75EF-AE7E-4122-B027-E85E9B46C38A Q39033012-DA366A82-F96C-4E6B-A39A-9CEBE0708BC1 Q40012685-18D3BD49-8A97-4009-A80C-2E96D1713601 Q41472938-1C63854A-969F-42CE-8A03-2E65FC5417A5 Q47106968-AED547CE-4D72-4724-A687-7798FF36B30D Q47732975-E1E455AF-A07A-4C98-A46F-A1AEE4BBF04C Q53490356-26AC41D0-8080-4942-A1CE-5371E5554114 Q57825092-128C8637-0FB7-4F46-A095-C374E4A92253

P2860

RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC

http://www.wikidata.org/entity/Q34446751

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@ast

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@en

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@nl

type

label

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@ast

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@en

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@nl

prefLabel

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@ast

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@en

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@nl

P1433

Q34446751-9194A2BC-E80D-43EE-9FB0-073EEFBB80E1

P1476

Q34446751-063EEF86-7358-482C-A4E8-10DA0E4F1244

P2093

Q34446751-21454B99-6908-4004-954A-4CFE092A3FE1

Q34446751-29FBA411-71C6-4866-9C29-39FCECD28947

Q34446751-3E4D48F3-D9D7-449B-A14A-819B1376151B

Q34446751-81F61954-08C7-4208-9B28-E959ACD4A723

Q34446751-9F186185-16AF-4F58-836C-831A73E50DC8

Q34446751-B0A24478-5DA1-4AC7-8DF3-CED585905941

Q34446751-E3648A5B-EA6B-4437-88B1-13044AF47F84

P2860

Q34446751-0362E9C5-7DF4-4569-B430-0F9AA489983F

Q34446751-0465979E-4B79-49F4-9824-B7C4FC394654

Q34446751-0D6F3F33-36D0-4553-9ED1-0044B1CDAEC3

Q34446751-14B9ABEB-A4BC-4C60-B050-02CA827E393D

Q34446751-15F57170-0377-46FA-9F54-A7470DB5E7FA

Q34446751-18B69600-077F-4A1E-88FF-122EAA6AE102

Q34446751-18BF20CE-2351-4623-800B-AE9E6448D861

Q34446751-257D93AD-7906-4B15-8E9F-295A12E9A9A9

Q34446751-2985DA30-0E5D-43E2-BD7E-056629856443

Q34446751-340620A7-69AB-45E1-A2B4-E68EDBF925E5

P304

Q34446751-A95E64A4-9F56-4DBE-B9A5-0253D99C2BA2

P31

Q34446751-2F56348B-F89F-478F-BAC8-FA6EA7B5CF2A

P356

Q34446751-8C123AED-1FD8-4F0A-B566-05269F344500

P407

Q34446751-EAE81845-19EE-460B-B606-79DD7CDC71E5

P433

Q34446751-8FA5F988-134C-4A86-BC0C-E784DC6A3924

P478

Q34446751-8407B150-087E-4A7F-B24A-CC029E77460C

P577

Q34446751-35BD9DE4-BE92-4EBF-80EE-2819B43F192E

P5875

Q34446751-0549C1A4-5CF8-438A-B8B4-BC7670903F26

P698

Q34446751-79DF9633-CB53-4A4F-AEF7-0D5C78DD4297

P921

Q34446751-D95D4B59-25B6-4348-B7FD-ECC32093A396

P932

Q34446751-0F5669F9-1C04-4508-8465-6F36C9D08D50

P356

JOURNAL.PONE.0043734

P1433

P1476

RAGE genetic polymorphisms are ...... n patients with advanced NSCLC

@en

P2093

Bin Wang

http://www.w3.org/2001/XMLSchema#string

Enhai Cui

http://www.w3.org/2001/XMLSchema#string

Feng Hua

http://www.w3.org/2001/XMLSchema#string

Huazong Zeng

http://www.w3.org/2001/XMLSchema#string

Wei Mao

http://www.w3.org/2001/XMLSchema#string

Xiang Wang

http://www.w3.org/2001/XMLSchema#string

Xueren Feng

http://www.w3.org/2001/XMLSchema#string

P2860

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer

Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.

Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients.

XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.

The receptor for advanced glycation end products (RAGE) and the lung.

Non small cell lung cancer (NSCLC): current status and future prospects.

Applications of genomics in NSCLC.

RAGE and RAGE ligands in cancer.

Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

Cloning, characterisation, and comparative quantitative expression analyses of receptor for advanced glycation end products (RAGE) transcript forms.

P304

e43734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0043734

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232257123

http://www.w3.org/2001/XMLSchema#string

P698

23071492

http://www.w3.org/2001/XMLSchema#string

P921

P932

3465300

http://www.w3.org/2001/XMLSchema#string